Cullinan Oncology, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 58,000 shares of Cullinan Oncology stock in a transaction on Monday, May 6th. The stock was sold at an average price of $28.07, for a total transaction of $1,628,060.00. Following the sale, the insider now owns 129,582 shares in the company, valued at approximately $3,637,366.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Cullinan Oncology Stock Performance
Shares of CGEM opened at $27.72 on Thursday. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -7.51 and a beta of -0.01. Cullinan Oncology, Inc. has a 52 week low of $7.64 and a 52 week high of $30.19. The business's fifty day moving average price is $18.95 and its two-hundred day moving average price is $14.13.
Cullinan Oncology (NASDAQ:CGEM - Get Free Report) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.96) by $0.42. As a group, research analysts forecast that Cullinan Oncology, Inc. will post -3.23 EPS for the current year.
Wall Street Analyst Weigh In
The Best AI Stock to Own in the World Today is Trading for Just $25
From Banyan Hill Publishing | Ad
“Titan of Tech” Bets Big on Tiny AI Company
He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal…
But our research shows his latest investment could be his most successful venture yet.
See how you can invest alongside him
Several research firms recently issued reports on CGEM. Wedbush started coverage on shares of Cullinan Oncology in a research report on Thursday, February 15th. They issued an "outperform" rating and a $30.00 price target for the company. William Blair assumed coverage on Cullinan Oncology in a research note on Monday, April 15th. They issued an "outperform" rating on the stock. Jonestrading lifted their price objective on Cullinan Oncology from $22.00 to $26.00 and gave the company a "buy" rating in a report on Wednesday, April 17th. HC Wainwright reduced their target price on Cullinan Oncology from $34.00 to $29.00 and set a "buy" rating on the stock in a report on Tuesday, April 16th. Finally, Stifel Nicolaus initiated coverage on Cullinan Oncology in a research report on Wednesday, May 1st. They issued a "buy" rating and a $40.00 price objective for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Cullinan Oncology has an average rating of "Buy" and an average target price of $31.00.
Get Our Latest Stock Analysis on Cullinan Oncology
Hedge Funds Weigh In On Cullinan Oncology
Several large investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Cullinan Oncology by 22.2% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 17,269 shares of the company's stock worth $294,000 after purchasing an additional 3,134 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of Cullinan Oncology by 81.6% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 8,996 shares of the company's stock valued at $153,000 after acquiring an additional 4,042 shares during the period. Parkman Healthcare Partners LLC boosted its stake in Cullinan Oncology by 20.8% during the 4th quarter. Parkman Healthcare Partners LLC now owns 529,877 shares of the company's stock worth $5,399,000 after acquiring an additional 91,132 shares during the last quarter. Affinity Asset Advisors LLC acquired a new position in Cullinan Oncology during the fourth quarter valued at approximately $3,057,000. Finally, NEOS Investment Management LLC bought a new position in shares of Cullinan Oncology during the fourth quarter worth $162,000. 86.31% of the stock is currently owned by institutional investors and hedge funds.
About Cullinan Oncology
(
Get Free Report)
Cullinan Oncology, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
